RESUMO
The utilization of d oxorubicin (DOX) is compromised by potential lethal cardiotoxicity in clinical application. Improving DOX efficacy in cancer cells while minimizing DOX-associated cardiotoxicity is in the forefront of research. Available methods at present include cardioprotective agents, DOX derivates and dosage schedules. This paper proposes new ideas on potential drug targets aiming at enhancing cancer therapy and cardioprotection simultaneously.
RESUMO
The utilization of doxorubicin (DOX) is compromised by potential lethal cardiotoxicity in clinical application. Improving DOX efficacy in cancer cells while minimizing DOX-associated cardiotoxicity is in the forefront of research. Available methods at present include cardioprotective agents, DOX derivates and dosage schedules. This paper proposes new ideas on potential drug targets aiming at enhancing cancer therapy and cardioprotection simultaneously.